A Novel Prognostic Score for 1‐Year Adverse Outcomes in Non‐ ACLF Cirrhotic Patients After Discharge: A Multicenter Prospective Cohort Study
Journal of Digestive Diseases · 2026-01 · 27 (1-2) · 63-74
DOI: 10.1111/1751-2980.70039 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Digestive Diseases, online erschienen am 23.02.2026. Verfasst von Yue Xiang Bian und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disea…. Hauptthemen laut MEDLINE: Liver Cirrhosis. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Shanghai Commissions of Science and Technology "Science and Technology Innovation Action Plan" Initiator Project (Yanfan Special Project).
Abstract (Originalsprache)
Objectives
Discharged cirrhotic patients hospitalized for acute decompensation (AD) without acute‐on‐chronic liver failure (ACLF) have heterogeneous long‐term prognosis; however, reliable prognostic tools are lacking. We aimed to identify the risk factors associated with 1‐year adverse outcomes including mortality and liver transplantation (LT) after patient’s discharge and to develop an evidence‐based prognostic model.
Methods
We enrolled 1212 and 621 cirrhotic patients who clinically improved after AD without ACLF before discharge from the Chinese AcuTe‐on‐CHronic LIver FailurE (CATCH‐LIFE) derivation and validation cohorts, respectively. The primary outcome was 1‐year adverse outcomes (all‐cause mortality or LT) post‐discharge. Independent risk factors for 1‐year post‐discharge adverse outcomes were identified using multivariable analysis, and a prognostic model was derived and validated.
Results
In the derivation cohort, 203 (16.7%) patients experienced 1‐year adverse outcomes and 370 (30.5%) were readmitted within 90 days post‐discharge. Age, prior decompensation, total bilirubin, international normalized ratio, albumin, and hemoglobin on discharge were independently associated with 1‐year post‐discharge adverse outcomes. The prognostic model achieved an area under the receiver operating characteristic curve (AUC) of 0.7767 (95% confidence interval [CI] 0.7408–0.8125) and 0.7274 (95% CI 0.6656–0.7892) in the derivation and validation cohorts. Using a risk threshold of ≥ 0.27, 17.70% of discharged non‐ACLF cirrhotic patients with AD in the validation cohort were classified as high‐risk, with 1‐year adverse outcome rate being 43.96%.
Conclusion
A prognostic model for predicting 1‐year adverse outcomes in discharged non‐ACLF cirrhotic patients was developed and validated, with a high‐risk cut‐off ≥ 0.27, which may effectively stratify adverse outcome risks at 1‐year post‐discharge and guide intensive post‐discharge management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Shanghai, China.
- Department of Gastroenterology and Hepatology, Kashgar Prefecture Second People's Hospital, Kashgar, Xinjiang Uygur Autonomous Region, China.
- Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
- Department of Infectious Diseases, Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
- Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
- Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.
ORCID-Profile: Xin Zheng, Yu Shi, Yu Bao Zheng
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Shanghai Commissions of Science and Technology "Science and Technology Innovation Action Plan" Initiator Project (Yanfan Special Project)
- Shanghai Commissions of Science and Technology Pujiang Program
Zitieren
APA
Bian, Y. X., Zhang, X., Wang, X. B., Zheng, X., Tan, W. T., Jiang, X. H., Huang, Y., Meng, Z. J., Gao, Y. H., Qian, Z. P., Liu, F., Lu, X. B., Shi, Y., Zheng, Y. B., He, Y. L., Wei, J. Y., Ji, P. X., He, K., Abuduaini, A., …, & Chinese (Acute on) Chronic Liver Failure Consortium (Ch‐CLIF.C) (2026). A Novel Prognostic Score for 1‐Year Adverse Outcomes in Non‐ ACLF Cirrhotic Patients After Discharge: A Multicenter Prospective Cohort Study. Journal of Digestive Diseases, 27(1-2), 63-74. https://doi.org/10.1111/1751-2980.70039
Vancouver
Bian YX, Zhang X, Wang XB, Zheng X, Tan WT, Jiang XH, et al. A Novel Prognostic Score for 1‐Year Adverse Outcomes in Non‐ ACLF Cirrhotic Patients After Discharge: A Multicenter Prospective Cohort Study. Journal of Digestive Diseases. 2026;27(1-2):63-74. doi:10.1111/1751-2980.70039
BibTeX
@article{Bian2026,
author = {Bian, Yue Xiang and Zhang, Xin and Wang, Xian Bo and Zheng, Xin and Tan, Wen Ting and Jiang, Xiu Hua and Huang, Yan and Meng, Zhong Ji and Gao, Yan Hang and Qian, Zhi Ping and Liu, Feng and Lu, Xiao Bo and Shi, Yu and Zheng, Yu Bao and He, Ying Li and Wei, Jian Yi and Ji, Pei Xuan and He, Kai and Abuduaini, Adila and Lu, Ya Wen and Qiao, Liang and Li, Hai and Chinese (Acute on) Chronic Liver Failure Consortium (Ch‐CLIF.C), Chinese (Acute on) Chronic Liver Failure Consortium (Ch‐CLIF.C)},
title = {A Novel Prognostic Score for 1‐Year Adverse Outcomes in Non‐ ACLF Cirrhotic Patients After Discharge: A Multicenter Prospective Cohort Study},
journal = {Journal of Digestive Diseases},
year = {2026},
volume = {27},
number = {1-2},
pages = {63--74},
doi = {10.1111/1751-2980.70039}
}
EUVIMED